Evidence map›Paper›PMID 40856812›Full record

ReviewClinical and experimental medicine2025

SLFN11, far from being limited to responding to cancer DNA damage.

Hao Xiao, Zeping Han, Yingkai Tang, Xukang Gao, Min Xu, Shuangjian Qiu, Ning Ren, Yong Yi, Chenhao Zhou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hao Xiao *Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Zeping Han *Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Yingkai Tang *The Second Clinical Medical School of Nanjing Medical University, Nanjing, 210029, Jiangsu, People's Republic of China.
Xukang GaoDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Min XuDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Shuangjian QiuDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Ning RenDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Yong YiDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China. yi.yong@zs-hospital.sh.cn.
Chenhao ZhouDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China. zhouchenhao@fudan.edu.cn.

Funding

National Natural Science Foundation of China 82072672National Natural Science Foundation of China 82472816
6 · The paper itself

Abstract

SLFN11, a member of the evolutionarily conserved SLFN gene family, is an interferon-stimulated early response gene. This review comprehensively explores its multifaceted roles. Structurally, its three distinct domains endow it with diverse functions. Epigenetic modifications, post-translational alterations, and multiple signaling pathways intricately regulate SLFN11 expression and activity. In terms of functions, it plays crucial roles in the DNA damage response during replication stress, distinct from traditional pathways. It also serves as a protector in the antiviral response and a valuable biomarker for predicting the efficacy of DNA-damaging agents and patient prognosis in various cancers. Beyond these, SLFN11 has non-canonical functions, including immune regulation, modulation of oncological behaviors, involvement in apoptosis, protection against proteotoxic stress, and association with Fanconi anemia. Looking ahead, SLFN11 holds great promise as a biomarker for personalized medicine, but challenges like developing accurate detection methods remain. In immunotherapy, understanding its dynamic changes is essential for optimizing treatment. Strategies to overcome SLFN11-low expression, such as epigenetic modulation, also need further investigation, which may open new avenues for disease treatment.

Indexed as

DNA DamageNeoplasmsNuclear ProteinsAnimalsBiomarkers, TumorEpigenesis, GeneticHumansSignal TransductionBiomarkers, TumorNuclear ProteinsSLFN11 protein, humanAntiviral functionBiomarkerDNA damage responseEpigenetic modificationImmune regulationOncological behaviorSchlafen 11

Identifiers

PMID40856812
PMCPMC12380651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.